Analytical Data
-
Gene name
MAP6
- Application
-
Alternative Names
MTAP6; N-STOP; STOP; Stable tubule-only polypeptide
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7TSJ2
-
Expression Region
Gln177~Glu387
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAP6, also known as microtubule-associated protein 6, plays a significant role in the organization and stabilization of microtubules within neuronal cells. This protein is crucial for the maintenance of cytoskeletal integrity, which is essential for various cellular processes, including axonal transport, cell polarity, and neuronal signaling. Research has shown that MAP6 is involved in neurodevelopment and may influence synaptic plasticity, making it a key factor in learning and memory. Abnormalities in MAP6 expression or function have been linked to several neurodegenerative disorders and psychiatric conditions, underscoring its potential as a therapeutic target. Recent advancements in recombinant protein technology have enabled researchers to produce MAP6 in a recombinant form, allowing for detailed studies of its structure-function relationships, interaction with microtubules, and role in cellular processes. By generating MAP6 as a recombinant protein, scientists can explore its biochemical properties and test its effects in cellular and animal models, providing insights into its physiological roles and implications in disease. This research not only enhances our understanding of MAP6 but also paves the way for potential interventions in conditions associated with MAP6 dysfunction.
